Pegylated interferon alpha-2b as adjuvant treatment of Stage II malignant melanoma: An evidence-based review

Core Evidence

Volumn 5, Issue , 2010, Pages 39-48

  Okuyama, Sonia ^a   Gonzalez, Rene ^a   Lewis, Karl D ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Adjuvant; Melanoma; Peg interferon; Pegylated interferon alpha 2b

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; PEGINTERFERON ALPHA2B;

ANOREXIA; ANTIGEN PRESENTATION; CANCER ADJUVANT THERAPY; CANCER RELAPSE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; COST EFFECTIVENESS ANALYSIS; DECREASED APPETITE; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FATIGUE; FEVER; FOLLOW UP; HAIRY CELL LEUKEMIA; HEADACHE; HIGH RISK PATIENT; HUMAN; KAPOSI SARCOMA; KIDNEY CARCINOMA; LIVER FUNCTION TEST; LOW DRUG DOSE; LYMPH NODE DISSECTION; LYMPHADENECTOMY; MELANOMA; MYALGIA; NAUSEA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT COMPLIANCE; PROGNOSIS; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REVIEW; SENTINEL LYMPH NODE BIOPSY; SIDE EFFECT; SOCIAL STATUS; UNSPECIFIED SIDE EFFECT;

EID: 79959369471     PISSN: 15551741     EISSN: None     Source Type: Journal    
DOI: 10.2147/CE.S8588     Document Type: Review

References (19)

1. Balch CM, Gershenwald JE, Soong S, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199-6206.
2. Riker Al, Radfar S, Liu S, et al. Immunotherapy of melanoma: A critical review of current concepts and future strategies. Expert Opin Biol Ther. 2007;7:345-358. (Pubitemid 46383477)
3. Kirkwood JM, Ernstoff MS. Interferons in the treatment of human cancer. J Clin Oncol. 1984;2:336-352. (Pubitemid 14107002)
4. Creagan ET, Ahmann DL, Frytak S, et al. Recombinant leukocyte A interferon (rIFN-alpha A) in the treatment of disseminated malignant melanoma. Analysis of complete and long-term responding patients. Cancer. 1986;58:2576-2578.
5. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996;14:7-17. (Pubitemid 26019991)
6. Kirkwood JM, Ibrahim JG, Sondak VK, et al. High and low dose interferon alfa-2b in high-risk melanoma: First analysis of Intergroup Trial E1690/S9111/C9190. J Clin Oncol. 2000;18:2444-2458. (Pubitemid 30415832)
7. Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U. A pooled analysis of Eastern Cooperative Oncology Group and Intergroup Trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res. 2004;10:1670-1677. (Pubitemid 38435557)
8. Wheatley K, Ives A, Eggermont J, et al. Interferon-alfa as adjuvant therapy for melanoma: An individual patient data meta-analysis of randomized trials. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol. 2007;25:Abstr 8526.
9. Mocellin S, Pasquali S, Rossi C, Nitti D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: A systematic review and meta-analysis. J Natl Cancer Inst. 2010;102:1-9.
10. Bukowski R, Ernstoff MS, Gore ME, et al. Pegylated interferon alfa-2b treatment for patients with solid tumors: A Phase I/II study. J Clin Oncol. 2002;20:3841-3849.
11. Glue P, Fang JW, Rouzier-Panis R, et al. Pegylated interferon-alfa2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin Pharmacol Ther. 2000;68:556-567.
12. Eggermont AMM, Suciu S, Santinami M, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected Stage III melanoma: Final results of EORTC 18991, a randomized phase III trial. Lancet. 2008;372:117-126. (Pubitemid 351952257)
13. Bottomley A, Coens C, Suciu S, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected Stage III melanoma: A Phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol. 2009;27:2916-2923.
14. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365-376. (Pubitemid 23073154)
15. Mohr P, Hauschild A, Trefzer U, et al. Health-related quality of life measures in melanoma patients receiving pulsed high-dose intravenous interferon alpha 2b. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol. 2007;25:Abstr 8526.
16. Cormier JN, Xing Y, Ding M, et al. Cost effectiveness of adjuvant interferon in node-positive melanoma. J Clin Oncol. 2007;25:2442-2448. (Pubitemid 46999215)
17. Dixon S, Walters SJ, Turner L, Hancock BW. Quality of life and cost-effectiveness of interferon-alpha in malignant melanoma: Results from randomized trial. Br J Cancer. 2006;94:492-498. (Pubitemid 43289752)
18. Crott R. Cost effectiveness and cost utility of adjuvant interferon alpha in cutaneous melanoma: A review. Pharmacoeconomics. 2004;22:569-580. (Pubitemid 38943102)
19. Kaehler KC, Sondak VK, Schadendorf D, et al. Pegylated interferons: Prospects for the use in the adjuvant and palliative therapy of metastatic melanoma. Eur J Cancer. 2010;46:41-46.